Tenofovir plus entecavir combination therapy for chronic hepatitis B with nucleos(t)ide analogue fai...
Tenofovir plus entecavir combination therapy for chronic hepatitis B with nucleos(t)ide analogue failure
About this item
Full title
Author / Creator
Publisher
Bursa: The Association of Health Research & Strategy
Journal title
Language
English
Formats
Publication information
Publisher
Bursa: The Association of Health Research & Strategy
Subjects
More information
Scope and Contents
Contents
Objectives: Currently, both entecavir (ETV) and tenofovir (TDF) are recommended first-line therapy for chronic hepatitis B treatment due to good tolerance, lower side-effect profile and high genetic barrier. However, mutations that may develop in the polymerase gene during treatment may result treatment failure. In this study, we aimed to evaluate t...
Alternative Titles
Full title
Tenofovir plus entecavir combination therapy for chronic hepatitis B with nucleos(t)ide analogue failure
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2431032263
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2431032263
Other Identifiers
ISSN
2149-3189
E-ISSN
2149-3189
DOI
10.18621/eurj.645852
